Clozapine

CHEMBL42 Phase 4 Đã phê duyệt Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

326.8 g/mol

LogP

3.1

Phase

4

An atypical antipsychotic reserved for treatment-resistant schizophrenia due to its risk of potentially fatal agranulocytosis, requiring regular blood monitoring. It acts on multiple neurotransmitter receptors and is highly effective in patients who have not responded to other antipsychotics.

Khối lượng phân tử

326,8000 g/mol

LogP

3,10

TPSA

30,90 Å²

Lipinski RO5

Đạt

Lĩnh vực điều trị

Pain Management Alzheimer's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Gastroesophageal Reflux Disease Chronic Kidney Disease Stroke Obesity Lymphoma Type 2 Diabetes Hypertension Major Depressive Disorder Chronic Pain Heart Failure Leukemia

Cơ chế tác dụng

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Cấu trúc 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1

InChI

InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3

Molecular Formula

C18H19ClN4

HBD / HBA

1 / 3

Liên kết có thể quay

1

Nguyên tử nặng

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

An atypical antipsychotic reserved for treatment-resistant schizophrenia due to its risk of potentially fatal agranulocytosis, requiring regular blood monitoring. It acts on multiple neurotransmitter receptors and is highly effective in patients who have not responded to other antipsychotics.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Clozapine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL42. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 135398737. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Bạn đang tìm kiếm thông tin thân thiện với bệnh nhân?

Clozapine trên PillFYI

Cấu trúc

Dữ liệu nhanh

Công thức: C18H19ClN4
Tên đồng nghĩa: 2

Liên kết ngoài

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.